CD8A and neoplasm: By blocking the PD-1/PD-L1 pathway through the administration of ICIs, anti-tumor CD8+ CTLs recognize autoantigens defined by HMC I on acinar and ductal epithelial cells and attack these cells, leading to the development of pSS-like disease (Figure 3).